Literature DB >> 19165225

p53 polymorphisms: cancer implications.

Catherine Whibley1, Paul D P Pharoah, Monica Hollstein.   

Abstract

The normal functioning of p53 is a potent barrier to cancer. Tumour-associated mutations in TP53, typically single nucleotide substitutions in the coding sequence, are a hallmark of most human cancers and cause dramatic defects in p53 function. By contrast, only a small fraction, if any, of the >200 naturally occurring sequence variations (single nucleotide polymorphisms, SNPs) of TP53 in human populations are expected to cause measurable perturbation of p53 function. Polymorphisms in the TP53 locus that might have cancer-related phenotypical manifestations are the subject of this Review. Polymorphic variants of other genes in the p53 pathway, such as MDM2, which might have biological consequences either individually or in combination with p53 variants are also discussed.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19165225     DOI: 10.1038/nrc2584

Source DB:  PubMed          Journal:  Nat Rev Cancer        ISSN: 1474-175X            Impact factor:   60.716


  179 in total

1.  p53 Codon 72 polymorphism predicts the pathologic response to neoadjuvant chemotherapy in patients with breast cancer.

Authors:  Ye Xu; Lihua Yao; Tao Ouyang; Jinfeng Li; Tianfeng Wang; Zhaoqing Fan; Benyao Lin; Youyong Lu; Yuntao Xie
Journal:  Clin Cancer Res       Date:  2005-10-15       Impact factor: 12.531

2.  A single nucleotide polymorphism in the MDM2 gene disrupts the oscillation of p53 and MDM2 levels in cells.

Authors:  Wenwei Hu; Zhaohui Feng; Lan Ma; John Wagner; J Jeremy Rice; Gustavo Stolovitzky; Arnold J Levine
Journal:  Cancer Res       Date:  2007-03-15       Impact factor: 12.701

3.  p53 suppresses the self-renewal of adult neural stem cells.

Authors:  Konstantinos Meletis; Valtteri Wirta; Sanna-Maria Hede; Monica Nistér; Joakim Lundeberg; Jonas Frisén
Journal:  Development       Date:  2006-01       Impact factor: 6.868

4.  Role of a p53 polymorphism in the development of human papillomavirus-associated cancer.

Authors:  A Storey; M Thomas; A Kalita; C Harwood; D Gardiol; F Mantovani; J Breuer; I M Leigh; G Matlashewski; L Banks
Journal:  Nature       Date:  1998-05-21       Impact factor: 49.962

5.  WT p53, but not tumor-derived mutants, bind to Bcl2 via the DNA binding domain and induce mitochondrial permeabilization.

Authors:  York Tomita; Natasha Marchenko; Susan Erster; Alice Nemajerova; Alexander Dehner; Christian Klein; Hongguang Pan; Horst Kessler; Petr Pancoska; Ute M Moll
Journal:  J Biol Chem       Date:  2006-01-26       Impact factor: 5.157

6.  Rescue of embryonic lethality in Mdm2-deficient mice by absence of p53.

Authors:  S N Jones; A E Roe; L A Donehower; A Bradley
Journal:  Nature       Date:  1995-11-09       Impact factor: 49.962

7.  Trp53-dependent DNA-repair is affected by the codon 72 polymorphism.

Authors:  M Siddique; K Sabapathy
Journal:  Oncogene       Date:  2006-02-06       Impact factor: 9.867

8.  Understanding the function-structure and function-mutation relationships of p53 tumor suppressor protein by high-resolution missense mutation analysis.

Authors:  Shunsuke Kato; Shuang-Yin Han; Wen Liu; Kazunori Otsuka; Hiroyuki Shibata; Ryunosuke Kanamaru; Chikashi Ishioka
Journal:  Proc Natl Acad Sci U S A       Date:  2003-06-25       Impact factor: 11.205

Review 9.  NAD(P)H:quinone oxidoreductase 1 (NQO1, DT-diaphorase), functions and pharmacogenetics.

Authors:  David Ross; David Siegel
Journal:  Methods Enzymol       Date:  2004       Impact factor: 1.600

10.  Mice heterozygous for mutation in Atm, the gene involved in ataxia-telangiectasia, have heightened susceptibility to cancer.

Authors:  Kevin Spring; Farida Ahangari; Shaun P Scott; Paul Waring; David M Purdie; Philip C Chen; Kevin Hourigan; Jonathan Ramsay; Peter J McKinnon; Michael Swift; Martin F Lavin
Journal:  Nat Genet       Date:  2002-08-26       Impact factor: 38.330

View more
  239 in total

Review 1.  The miR-29 family: genomics, cell biology, and relevance to renal and cardiovascular injury.

Authors:  Alison J Kriegel; Yong Liu; Yi Fang; Xiaoqiang Ding; Mingyu Liang
Journal:  Physiol Genomics       Date:  2012-01-03       Impact factor: 3.107

2.  AKT-dependent phosphorylation of Niban regulates nucleophosmin- and MDM2-mediated p53 stability and cell apoptosis.

Authors:  Haitao Ji; Zhiyong Ding; David Hawke; Dongming Xing; Bing-Hua Jiang; Gordon B Mills; Zhimin Lu
Journal:  EMBO Rep       Date:  2012-06-01       Impact factor: 8.807

3.  S6K1 is a multifaceted regulator of Mdm2 that connects nutrient status and DNA damage response.

Authors:  Keng Po Lai; Wai Fook Leong; Jenny Fung Ling Chau; Deyong Jia; Li Zeng; Huijuan Liu; Lin He; Aijun Hao; Hongbing Zhang; David Meek; Chakradhar Velagapudi; Samy L Habib; Baojie Li
Journal:  EMBO J       Date:  2010-07-23       Impact factor: 11.598

4.  TP53 Arg72Pro polymorphism and endometrial cancer risk: a meta-analysis.

Authors:  De-Ke Jiang; Lei Yao; Wei-Hua Ren; Wen-Zhang Wang; Bo Peng; Long Yu
Journal:  Med Oncol       Date:  2010-06-15       Impact factor: 3.064

5.  Alterations of the p53 and PIK3CA/AKT/mTOR pathways in angiosarcomas: a pattern distinct from other sarcomas with complex genomics.

Authors:  Antoine Italiano; Chun-Liang Chen; Rachael Thomas; Matthew Breen; Françoise Bonnet; Nicolas Sevenet; Michel Longy; Robert G Maki; Jean-Michel Coindre; Cristina R Antonescu
Journal:  Cancer       Date:  2012-05-30       Impact factor: 6.860

6.  The p53 Codon 72 Polymorphism Modifies the Cellular Response to Inflammatory Challenge in the Liver.

Authors:  Julia I-Ju Leu; Maureen E Murphy; Donna L George
Journal:  J Liver       Date:  2013

7.  The association between polymorphism of P53 Codon72 Arg/Pro and hepatocellular carcinoma susceptibility: evidence from a meta-analysis of 15 studies with 3,704 cases.

Authors:  Surong Hu; Lianying Zhao; Jingting Yang; Miao Hu
Journal:  Tumour Biol       Date:  2013-12-11

8.  The Role of the O-GlcNAc Modification in Regulating Eukaryotic Gene Expression.

Authors:  Sandii Brimble; Edith E Wollaston-Hayden; Chin Fen Teo; Andrew C Morris; Lance Wells
Journal:  Curr Signal Transduct Ther       Date:  2010

9.  The future of primary intraocular lymphoma (retinal lymphoma).

Authors:  Chi-Chao Chan; Sylvain Fisson; Bahram Bodaghi
Journal:  Ocul Immunol Inflamm       Date:  2009 Nov-Dec       Impact factor: 3.070

Review 10.  Mechanisms of drug resistance in colon cancer and its therapeutic strategies.

Authors:  Tao Hu; Zhen Li; Chun-Ying Gao; Chi Hin Cho
Journal:  World J Gastroenterol       Date:  2016-08-14       Impact factor: 5.742

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.